search
IBRX
Trends
- 1Retail Traders Speculate SLS, IBRX Could Join Nasdaq-100 After Moderna▼SLS, IBRX Stocks Draw Retail Chatter As MRNA Lands A Nasdaq-100 Spot – ‘It Will Be SLS Next’
Retail investors are speculating that small-cap biotechs Sellas Life Sciences (SLS) and Immatics-adjacent name IBRX could be next in line for Nasdaq-100 inclusion, after Moderna (MRNA) landed a spot in the index. Traders argue index eligibility could drive sharp rallies in the smaller stocks, with one saying 'it will be SLS next'. Nasdaq-100 additions typically trigger buying from index funds tracking the benchmark.
- 2SLS Stock Rises Overnight as Retail Traders Pick Sellas as Most Bullish Play●SLS Stock Rises Overnight: Why Retail Traders Prefer Sellas Over IBRX, ONDS, PYPL As Most Bullish Pick
Sellas Life Sciences (SLS) shares climbed in overnight trading, with retail traders naming it a more bullish pick than Immunicom-linked peer IBRX, Ondas (ONDS) and PayPal (PYPL). Traders on social platforms compared the stocks, favoring SLS for its momentum and speculative upside despite its small-cap risk profile.